|
1 |
1. Räber L, Wohlwend L, Wigger M, et al. Fiveyear clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the SirolimusEluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819-2828. Abstract 2. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111:453-462. Abstract 3. Moses JW, Leon MB, Popma JJ, et al. Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323. Abstract 4. Stone GW, Ellis SG, Cox DA, et al. A polymerbased, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231. Abstract 5. Morice M, Colombo A, Meier B, et al; REALITY trial investigators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: a randomized controlled trial. JAMA. 2006;295:895-904. Abstract 6. Galloe AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008;299:409-416. Abstract 7. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-662. Abstract 8. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57:1700-1708. Abstract 9. Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV. Circulation. 2012;125:1246-1255. Abstract 10. Jensen LO, Thayssen P, Christiansen EH, et al; for the SORT OUT IV Investigators. 2-Year patientrelated versus stent-related outcomes: The SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) trial. J Am Coll Cardiol. 2012;60:1140-1147. Abstract 11. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention. 2006;2:286-294. Abstract 12. Claessen BE, Beijk MA, Legrand V, et al. Twoyear clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimuseluting stent in the treatment of patients with de novo native coronary artery lesions: The SPIRIT II trial. Circ Cardiovasc Intervent. 2009;2:339-347. 13. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA. 2008;299:1903-1913. Abstract 14. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-1674. Abstract 15. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-209. Abstract 16. Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: The RESOLUTE US clinical trial. J Am Coll Cardiol. 2011;57:17781783.Abstract 17. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146. Abstract 18. Birgelen C, Basalus MWZ, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: The TWENTE Trial. J Am Coll Cardiol. 2012;59:1350-1361. Abstract |